PIM
NBIX icon

Plato Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Plato Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$525K Hold
3,981
– – 0.04% 343
2025
Q4 		$567K Buy
3,981
+1,672
+72% +$242K 0.04% 335
2025
Q3 		$322K Buy
2,309
+27
+1% +$3.66K 0.02% 370
2025
Q2 		$286K Hold
2,282
– – 0.02% 387
2025
Q1 		$255K Sell
2,282
-8,562
-79% -$1.08M 0.02% 381
2024
Q4 		$1.49M Sell
10,844
-129
-1% -$16K 0.11% 192
2024
Q3 		$1.26M Buy
10,973
+10,548
+2,482% +$1.45M 0.1% 209
2024
Q2 		$58.5K Buy
425
+130
+44% +$17.8K 0.01% 393
2024
Q1 		$40.7K Buy
+295
New +$40.3K ﹤0.01% 387

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Plato Investment Management's NBIX Position: Q1 2026 in Review

Plato Investment Management held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 3,981 shares worth $525K. The position accounts for 0.04% of the portfolio, ranked #343.

Plato Investment Management first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.49M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Plato Investment Management held 3,981 shares of Neurocrine Biosciences worth $525K as of Q1 2026.
  • Plato Investment Management left its Neurocrine Biosciences share count unchanged in Q1 2026.
  • Neurocrine Biosciences made up 0.04% of Plato Investment Management's portfolio in Q1 2026, its #343 holding.
  • Plato Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
  • Plato Investment Management's Neurocrine Biosciences position peaked at $1.49M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Plato Investment Management's 13F filing for Q1 2026, filed 5 May 2026.